
Datasheet

Version: 3.0.0 Revision date: 02 Jun 2025



B-Cell CLL/Lymphoma 9 Like Protein (BCL9L) Antibody

Catalogue No.:abx031265



Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1 (By similarity).

Target: B-Cell CLL/Lymphoma 9 Like Protein (BCL9L)

Clonality: Polyclonal

Reactivity: Human

Tested Applications: ELISA, WB

Host: Rabbit

Recommended dilutions: WB: 1/1000. Optimal dilutions/concentrations should be determined by the end user.

Conjugation: Unconjugated

Immunogen: KLH-conjugated synthetic peptide between 147-176 amino acids from the N-terminal region of

human BCL9L.

Isotype: IgG

Form: Liquid

Purification: Purified through a protein A column, followed by peptide affinity purification.

Storage: Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

UniProt Primary AC: Q86UU0 (<u>UniProt</u>, <u>ExPASy</u>)

Gene Symbol: BCL9L

1 of 2

Datasheet

Version: 3.0.0 Revision date: 02 Jun 2025



KEGG: hsa:283149

String: <u>9606.ENSP00000335320</u>

Molecular Weight: Calculated MW: 157 kDa

Buffer: PBS containing 0.09% sodium azide.

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC.

THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL

CONSUMPTION.